Press release
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results
FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host conference call and webcast today, Mar. 11, 2025, at 4:30 p.m. ET CELEBRATION, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the fourth quarter and full year ended Dec. 31, 2024. “2024 was a transformational year for Zevra. We emerged as a commercial stage company and are executing on the opportunity to positively impact the lives of people living with rare diseases,” said Neil F. McFarlane, Zevra’s President and Chief Executive Officer. “We are starting 2025 from a position of strength. Our priorities are guided by Zevra’s strategic plan, unveiled during our third quarter call and categorized under four actionable pillars: commercial excellence, pipeline and innovation, talent and culture, and corporate foundation.” Commercial Excellence Initiated commercial launch of MIPLYFFA immediately following U.S. FDA approval on Sep. 20, 2024, and organized U.S. commercial availability on Nov. 21, 2024, at the early end of the company’s guidance.As of Dec. 31, 2024, Zevra received 109 total prescription enrollment forms for MIPLYFFA, including all active U.S. Expanded Access Program (EAP) participants. To date in this early phase of the launch, patients have received payor authorization through direct formulary coverage or via the medical exception process as Zevra’s market access team continues to engage with payors to formalize coverage.OLPRUVA® had 4 new patient enrollments during Q4 2024 as the team began to execute on its strategy to target adult UCD patients with an active lifestyle where enhanced portability and ease of administration is an important benefit; market access remains consistent at 76% of covered lives. Pipeline and Innovation With receipt of the U.S. approval for MIPLYFFA, regulatory approval in the EU is a key priority. Filing of the Marketing Authorisation Application with the European Medicines Agency (EMA) is targeted for the second half of 2025.New data presented during the WORLDSymposium included eight (8) poster presentations...